Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Intensive chemotherapy offers pluses, minuses in advanced endometrial cancer

01.09.2005


Complex chemotherapy cocktails offer about one extra month of life to patients with end-stage endometrial cancer but also can result in severe, possibly fatal, side effects, according to the first systematic review of studies addressing the topic.



“ The best drug treatment for women with advanced cancer of the womb is still not clear,” concludes the review, led by Dr. Caroline Humber of Walsgrave Hospital in England.

The review appears in the current issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.


The authors identified 11 randomized controlled trials with 2,288 participants. All compared one or more of the commonly used chemotherapy agents with an alternative drug, combination, or dosing schedule.

Six of the trials compared combinations of three or more drugs to simpler regimens. A combined analysis for all 1,135 women showed that the more intense treatments did a better job of controlling tumor growth, yet no drug combination stood out as superior.

But increasing the number of chemotherapy drugs also increased the likelihood of serious damage to the heart, kidneys, nerves, digestive system, blood cells and other body systems. The studies reported as many as 12 possible treatment-related deaths.
Among the drugs compared were paclitaxel, cisplatin, doxorubicin and 5-fluoracil.
Dr. Ira Horowitz, a gynecologic oncologist at Emory University, says that patients with advanced endometrial cancer are generally older and often have multiple health problems related to obesity and diabetes.

“ When you’re 60, 70, 80 years old with advanced endometrial cancer, it’s much more difficult to tolerate the drugs and the side effects. …They may not get that payback for what it’s going to take out of them.”

The review authors had set out to answer the kinds of questions that patients ask when considering treatment options, says Humber. “They ask ‘Will this make me live longer? Will this make my cancer stay away for longer? Will it make me feel better? Will it help my symptoms?’”

These questions remain largely unanswered. The authors could locate no studies that compared chemotherapy for advanced endometrial cancer with other options such as hormone therapy, comfort care or no treatment. Moreover, none of the studies examined symptom control and quality of life issues.

“ It would be nice to know what the quality of life was,” says Humber. “In other types of cancer that we treat, for example lung cancer, we do see very small gains in survival but absolutely enormous gains in quality of life reported by patients. ... But we don’t know that for this condition.”

The report says that collection of such patient-reported data should be a priority in future research. “ What ought to come out of this is that we need to continue to recruit patients into well-designed trials,” says Humber. Yet, because of the relative rarity of the condition and the frequency of co-existing health problems, recruiting enough participants for a thorough study can be a long, slow process.

For example, Dr. David Scott Miller — a professor of obstetrics and gynecology at the University of Texas Southwestern Medical Center — is leading a government-funded study that is seeking 900 participants. Miller and his colleagues will compare survival rates, quality of life and side effects of two widely used drug combinations. They aim to complete the study within five years.

“ We hope [the Cochrane findings] might spur people to participate,” says Miller. “There are about 6,000 or 7,000 women who are likely to die of endometrial cancer in the United States annually. Those patients would all be appropriate candidates for chemotherapy and for our trial.”

Because early-stage endometrial cancer can usually be cured by surgical removal of the uterus, advanced stages are relatively rare. About 50,000 deaths occur each year worldwide. The condition is most common in North America and Europe, and risk factors include obesity, hypertension, diabetes and hormone replacement therapy.

Humber C, et al. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. The Cochrane Database of Systematic Reviews 2005, Issue 3.

The Cochrane Collaboration is an international nonprofit, independent organization that produces and disseminates systematic reviews of health care interventions and promotes the search for evidence in the form of clinical trials and other studies of interventions.

Carolyn Humber | EurekAlert!
Further information:
http://www.hbns.org
http://www.cfah.org
http://www.cochrane.org

More articles from Health and Medicine:

nachricht One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center

nachricht The gut microbiota plays a key role in treatment with classic diabetes medication
01.06.2017 | University of Gothenburg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Quantum thermometer or optical refrigerator?

23.06.2017 | Physics and Astronomy

A 100-year-old physics problem has been solved at EPFL

23.06.2017 | Physics and Astronomy

Equipping form with function

23.06.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>